Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/7/2023 | $69.00 | Buy | Mizuho |
4/18/2023 | Outperform | TD Cowen | |
1/3/2023 | $52.00 → $58.00 | Buy | Needham |
12/15/2022 | $66.00 | Buy | Guggenheim |
11/17/2022 | $69.00 | Buy | BTIG Research |
12/29/2021 | $50.00 | Buy | Jefferies |
6/24/2021 | $50.00 | Buy | Jefferies |
Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00
TD Cowen initiated coverage of Vaxcyte with a rating of Outperform
Needham reiterated coverage of Vaxcyte with a rating of Buy and set a new price target of $58.00 from $52.00 previously
Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:PCVX) with a Buy and maintains $95 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight.
Cantor Fitzgerald analyst Louise Chen reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight.
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- -- At All Doses Studied, VAX-31 Was Observed to be Well Tolerated and Demonstrated a Safety Profile Similar to Prevnar 20® -- -- Topline Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver Broadest-Spectrum Pneumococcal Conjugate Vaccine Candidates that Provide Protection Against Both Currently Circulating and Historically Prevalent Serotypes -- -- For Adult Indication, VAX-31 Selected to Advance to Phase 3 Program; Vaxcyte Plans
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. To participate in the conference call, please dial 800-225-9448 (domest
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international) and refer to conference ID PCVXQ423. A live we
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
4 - Vaxcyte, Inc. (0001649094) (Issuer)
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 -- -- VAX-31, Designed to Cover Currently Circulating and Historically Prevalent Strains, is Being Studied for the Prevention of Invasive Pneumococcal Disease in the Pediatric and Adult Populations -- SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- PCV Pediatric Indication: VAX-24 Infant Phase 2 Study Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025; Initiation of VAX-31 Infant Phase 2 Study Expected in First Quarter of 2025 Subject to IND Application Clearance by
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About VaxcyteVaxcyte is a vaccine innova
144 - Vaxcyte, Inc. (0001649094) (Subject)
10-Q - Vaxcyte, Inc. (0001649094) (Filer)
8-K - Vaxcyte, Inc. (0001649094) (Filer)
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. "We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte's Board of Directors as we continue to realize our mission of developing vaccines to address serious bacterial illnesses," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "Jacks will provide strategic insights across
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)